SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-20-000065
Filing Date
2020-10-08
Accepted
2020-10-08 16:01:24
Documents
14
Period of Report
2020-10-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K xers-20201008.htm   iXBRL 8-K 48312
  Complete submission text file 0001346302-20-000065.txt   224056

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20201008.xsd EX-101.SCH 2420
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20201008_cal.xml EX-101.CAL 708
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20201008_def.xml EX-101.DEF 15623
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20201008_lab.xml EX-101.LAB 30040
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20201008_pre.xml EX-101.PRE 16292
7 EXTRACTED XBRL INSTANCE DOCUMENT xers-20201008_htm.xml XML 11507
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 201231024
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences